140 filings
Page 3 of 7
8-K
u3oloa hnlqn
14 Mar 16
Other Events
12:00am
8-K
ypq9vykchid5p8lle
16 Oct 15
Entry into a Material Definitive Agreement
12:00am
424B5
yojbt48tor2
16 Oct 15
Prospectus supplement for primary offering
12:00am
8-K
y42ezrgmrhmc7
24 Aug 15
CelatorĀ® Pharmaceuticals Appoints Michael R. Dougherty as Executive Chairman of Board of Directors
12:00am
8-K
3v20x5msdr7 93wtumjb
16 Jul 15
Regulation FD Disclosure
12:00am
8-K
sezgrto jfa8r
24 Jun 15
CPX-351 demonstrates a 43.2% relative improvement in induction response rate
12:00am
8-K
cr4ju18 mszh
12 Jun 15
Submission of Matters to a Vote of Security Holders
12:00am
8-K
6k4ct6mig0z0d6z
31 Mar 15
Entry into a Material Definitive Agreement
12:00am
8-K
kxof1y
3 Mar 15
CelatorĀ® Pharmaceuticals Appoints Jean-Pierre Bizzari to Board of Directors
12:00am
8-K
iee x3j7kjuf
23 Dec 14
Other Events
12:00am
8-K
8yfljyu520a2r yk
8 Dec 14
Regulation FD Disclosure
12:00am
8-K
7htq 344kkjd5wrax2
27 Oct 14
CelatorĀ® Pharmaceuticals Announces Phase 3 Clinical Study of CPX-351 Achieved Target Enrollment In High Risk (Secondary) Acute Myeloid Leukemia
12:00am
424B5
fpdy4 sxo3z4n6cp8
23 Oct 14
Prospectus supplement for primary offering
12:00am